LAWRENCE, Mass., Feb. 3, 2017 /PRNewswire/ -- NxStage
Medical, Inc. (Nasdaq: NXTM), a leading medical technology company
focused on advancing renal care, today announced that Allan Collins, M.D., FACP, a recognized
worldwide leader in nephrology, has joined NxStage as Chief Medical
Officer to help continue to advance NxStage's innovative pipeline
and to expand patient access to its life-changing therapies. In
this new position, Collins will lead a new Medical Affairs team in
addition to continuing his current role as chair of the Company's
Scientific Advisory Board.
"I'm excited to continue integrating medical insights with a
robust dataset to engage key opinion leaders and expand patient
access to NxStage's life-changing therapies," stated Dr. Collins.
"I look forward to collaborating with all the teams at NxStage to
bring its innovative solutions to more patients."
"As the head of our Scientific Advisory board, Allan has been
instrumental in building a body of clinical evidence that includes
key data measuring comparative effectiveness of therapy with the
NxStage System One," stated Joe
Turk, President of NxStage. "In this new role, Allan will
also be leading our efforts to develop and communicate clinical
data that is of the highest relevance to customers to enhance
patient access and strengthen physician understanding of our
therapies. We are delighted to have him as part of the team as
NxStage continues to advance our innovative pipeline and expand our
addressable market."
Dr. Collins is a Professor of Medicine at the University of
Minnesota. He is the Director of the Chronic Research Disease
Group, an interdisciplinary biomedical research group committed to
the investigation of chronic illnesses to improve public health,
and as part of this, served as the coordinating center for the
United States Renal Data System (USRDS) and its Annual Data Report
from 2000 through 2014. Dr. Collins was presented the
Distinguished Service Award by the National Kidney Foundation (NKF)
in 2003, and served as the President of the NKF from 2006 through
2008. In 2014, Dr. Collins received the ASN Belding Scribner Award
and the American Association of Kidney Patients Medal of Excellence
Award. He has over 200 clinical publications, and is an invited
lecturer worldwide. Dr. Collins has led the Company's Scientific
Advisory Board as Chief Medical Advisor since 2014.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a leading medical
technology company, headquartered in Lawrence, Massachusetts, USA, that develops,
manufactures and markets innovative products for the treatment of
end-stage renal disease (ESRD) and acute kidney failure. NxStage
also has established a small number of dialysis clinics committed
to the development of innovative care delivery models for patients
with ESRD. For more information on NxStage and its products and
services, please visit the Company's websites at www.nxstage.com
and www.nxstagekidneycare.com.
Forward-Looking Statements
This release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this release that are not clearly historical in nature are
forward-looking, and the words "anticipate," "believe," "expect,"
"estimate," "plan," and similar expressions are generally intended
to identify forward-looking statements. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors including those that are
discussed in NxStage's filings with the Securities and Exchange
Commission, including its Quarterly Report on Form 10-Q for the
quarter ended September 30, 2016.
NxStage is under no obligation to (and expressly disclaims any such
obligation to) update or alter its forward-looking statements,
whether as a result of new information, future events or
otherwise.
Media contact:
Kristen K. Sheppard, Esq.
ksheppard@nxstage.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nxstage-announces-appointment-of-chief-medical-officer-300401867.html
SOURCE NxStage Medical, Inc.